http://www.drugnewswire.com/10971/
January 5, 2007 (DrugNewswire)- Boston Life Sciences, Inc. (NASDAQ:BLSI) , a biotechnology company focused on diagnostic and therapeutic products for central nervous system disorders, announced today that it has entered into an exclusive, worldwide license with BioAxone Therapeutic Inc. of Montreal, Canada, to develop and commercialize Cethrin as well as other specified compounds subject to the license to treat acute spinal cord injury (SCI) and other serious central nervous system disorders. The license provides for an up-front license fee, possible performance milestones, and on-going royalties based on sales of Cethrin after approval…